Exjade (deferasirox)-Important Safety Information from Novartis as approved by the IMB
10 July 2008
Please find herewith an important safety communication from Novartis regarding Exjade (deferasirox) and hepatic failure, need for hepatic monitoring, gastrointentinal haemorrhage and ulceration, and renal tubulopathy.